Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TATE with tirazamine vs conventional TACE in intermediate-stage hepatocellular carcinoma
CTR20243479Phase 3Active
- Sponsor
- Ruizhen Pharmaceutical
- Start
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tirazamine in hepatocellular carcinoma (HCC) (2 arms), sponsored by Ruizhen Pharmaceutical. Primary endpoint: Progression-free survival (PFS). Started Mar 2025; status: active.
02
Drugs
tirazamine
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20243479.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243479.